However, current therapies targeting the VEGF/VEGFR-2 pathway, such as TKIs and monoclonal antibodies, have shown limited clinical efficacy in PC, primarily because of the emergence of resistance and the activation of compensatory pathways. This evidence concerns the gene KDR and pachyonychia congenita.